Show simple item record

dc.contributor.authorDelgado, Julio
dc.contributor.authorThomson, Kirsty J
dc.contributor.authorRussell, Nigel
dc.contributor.authorEwing, Joanne
dc.contributor.authorStewart, Wendy
dc.contributor.authorCook, Gordon
dc.contributor.authorDevereux, Stephen
dc.contributor.authorLovell, Richard
dc.contributor.authorChopra, Rajesh
dc.contributor.authorMarks, David I
dc.contributor.authorMackinnon, Stephen
dc.contributor.authorMilligan, Donald W
dc.date.accessioned2009-07-07T10:26:22Z
dc.date.available2009-07-07T10:26:22Z
dc.date.issued2006-02-15
dc.identifier.citationResults of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. 2006, 107 (4):1724-30 Blooden
dc.identifier.issn0006-4971
dc.identifier.pmid16239425
dc.identifier.doi10.1182/blood-2005-08-3372
dc.identifier.urihttp://hdl.handle.net/10541/72684
dc.description.abstractWe report results in 41 consecutive patients with chronic lymphocytic leukemia (CLL) who underwent allogeneic hematopoietic cell transplantation (HCT) after fludarabine, melphalan, and alemtuzumab conditioning. Donors were 24 HLA-matched siblings and 17 unrelated volunteers, 4 of them mismatched with recipients. All but 3 patients had initial hematologic recovery, but 5 more patients had secondary graft failure. Median intervals to neutrophil (greater than 0.5 x 10(9)/L) and platelet (greater than 20 x 10(9)/L) recovery were 14 days (range, 9-30 days) and 11 days (range, 8-45 days), respectively. Eleven (27%) patients had relapses and received escalated donor lymphocyte infusions, but only 3 of them had sustained responses. Acute and chronic graft-versus-host disease (GVHD) was observed in 17 (41%) and 13 (33%) patients, respectively. Seventeen (41%) patients have died, 5 of progressive disease. The 2-year overall survival and transplantation-related mortality (TRM) rates were 51% (95% confidence interval [CI], 33%-69%) and 26% (95% CI, 14%-46%), respectively. The alemtuzumabbased regimen was feasible and effective in patients with CLL with a relatively low rate of GVHD. However, TRM remains relatively high as a result of a variety of viral and fungal infections. Studies are ongoing to address the efficacy of reduced doses of alemtuzumab in this group of immunosuppressed patients.
dc.language.isoenen
dc.subjectCancer Antibodiesen
dc.subjectLeukaemiaen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntibodies, Neoplasm
dc.subject.meshAntineoplastic Agents
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshFollow-Up Studies
dc.subject.meshGraft vs Host Disease
dc.subject.meshHistocompatibility Testing
dc.subject.meshHumans
dc.subject.meshLeukemia, Lymphocytic, Chronic, B-Cell
dc.subject.meshMiddle Aged
dc.subject.meshStem Cell Transplantation
dc.subject.meshSurvival Analysis
dc.subject.meshTime Factors
dc.subject.meshTissue Donors
dc.subject.meshTransplantation Chimera
dc.subject.meshTransplantation, Homologous
dc.subject.meshTreatment Failure
dc.subject.meshTreatment Outcome
dc.titleResults of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study.en
dc.typeArticleen
dc.contributor.departmentDepartment of Hematology, Birmingham Heartlands Hospital, Birmingham, B9 5SS, United Kingdom.en
dc.identifier.journalBlooden
html.description.abstractWe report results in 41 consecutive patients with chronic lymphocytic leukemia (CLL) who underwent allogeneic hematopoietic cell transplantation (HCT) after fludarabine, melphalan, and alemtuzumab conditioning. Donors were 24 HLA-matched siblings and 17 unrelated volunteers, 4 of them mismatched with recipients. All but 3 patients had initial hematologic recovery, but 5 more patients had secondary graft failure. Median intervals to neutrophil (greater than 0.5 x 10(9)/L) and platelet (greater than 20 x 10(9)/L) recovery were 14 days (range, 9-30 days) and 11 days (range, 8-45 days), respectively. Eleven (27%) patients had relapses and received escalated donor lymphocyte infusions, but only 3 of them had sustained responses. Acute and chronic graft-versus-host disease (GVHD) was observed in 17 (41%) and 13 (33%) patients, respectively. Seventeen (41%) patients have died, 5 of progressive disease. The 2-year overall survival and transplantation-related mortality (TRM) rates were 51% (95% confidence interval [CI], 33%-69%) and 26% (95% CI, 14%-46%), respectively. The alemtuzumabbased regimen was feasible and effective in patients with CLL with a relatively low rate of GVHD. However, TRM remains relatively high as a result of a variety of viral and fungal infections. Studies are ongoing to address the efficacy of reduced doses of alemtuzumab in this group of immunosuppressed patients.


This item appears in the following Collection(s)

Show simple item record